Rare Protein-Truncating Variants in <i>APOB</i> , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease
-
- Gina M. Peloso
- Department of Biostatistics, Boston University School of Public Health, MA (G.M.P.).
-
- Akihiro Nomura
- Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan (A. Nomura, A. Nohara, M.K., H.T.).
-
- Amit V. Khera
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (A.V.K., M.C., S.K.).
-
- Mark Chaffin
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (A.V.K., M.C., S.K.).
-
- Hong-Hee Won
- Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea (H.-H.W.).
-
- Diego Ardissino
- Cardiology, Azienda Ospedaliero-Universitaria di Parma, University of Parma, Parma, Italy (D.A.).
-
- John Danesh
- MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (J.D.), University of Cambridge, Cambridge, United Kingdom.
-
- Heribert Schunkert
- Deutsches Herzzentrum München, Technische Universität München, Deutsches Zentrum für Herz-Kreislauf-Forschung, München, Germany (H.S.).
-
- James G. Wilson
- Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS (J.G.W.).
-
- Nilesh Samani
- Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (N.S.).
-
- Jeanette Erdmann
- Institute for Integrative and Experimental Genomics, University of Lübeck, Germany (J.E.).
-
- Ruth McPherson
- University of Ottawa Heart Institute, Ottawa, Canada (R.M.).
-
- Hugh Watkins
- Cardiovascular Medicine, Radcliffe Department of Medicine and Wellcome Trust Center for Human Genetics, University of Oxford, Oxford, United Kingdom (H.W.).
-
- Danish Saleheen
- Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (D.S.).
-
- Shane McCarthy
- Regeneron Genetics Center, Tarrytown, NY (S.M., T.M.T., F.E.D., A.B.).
-
- Tanya M. Teslovich
- Regeneron Genetics Center, Tarrytown, NY (S.M., T.M.T., F.E.D., A.B.).
-
- Joseph B. Leader
- Geisinger Health System, Danville, PA (J.B.L., H.L.K., D.J.C.).
-
- H. Lester Kirchner
- Geisinger Health System, Danville, PA (J.B.L., H.L.K., D.J.C.).
-
- Jaume Marrugat
- Registre Gironí del Cor group, IMIM (Hospital del Mar Research Institute), Barcelona, Spain (J.M.). CIBER Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain (J.M.).
-
- Atsushi Nohara
- Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan (A. Nomura, A. Nohara, M.K., H.T.).
-
- Masa-aki Kawashiri
- Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan (A. Nomura, A. Nohara, M.K., H.T.).
-
- Hayato Tada
- Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan (A. Nomura, A. Nohara, M.K., H.T.).
-
- Frederick E. Dewey
- Regeneron Genetics Center, Tarrytown, NY (S.M., T.M.T., F.E.D., A.B.).
-
- David J. Carey
- Geisinger Health System, Danville, PA (J.B.L., H.L.K., D.J.C.).
-
- Aris Baras
- Regeneron Genetics Center, Tarrytown, NY (S.M., T.M.T., F.E.D., A.B.).
-
- Sekar Kathiresan
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (A.V.K., M.C., S.K.).
抄録
<jats:sec> <jats:title>Background</jats:title> <jats:p> Familial hypobetalipoproteinemia is a genetic disorder caused by rare protein-truncating variants (PTV) in the gene encoding <jats:italic>APOB</jats:italic> (apolipoprotein B), the major protein component of LDL (low-density lipoprotein) and triglyceride-rich lipoprotein particles. Whether heterozygous <jats:italic>APOB</jats:italic> deficiency is associated with decreased risk for coronary heart disease (CHD) is uncertain. We combined family-based and large scale gene-sequencing to characterize the association of rare PTVs in <jats:italic>APOB</jats:italic> with circulating LDL-C (LDL cholesterol), triglycerides, and risk for CHD. </jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p> We sequenced the <jats:italic>APOB</jats:italic> gene in 29 Japanese hypobetalipoproteinemia families, as well as 57 973 individuals derived from 12 CHD case-control studies—18 442 with early-onset CHD and 39 531 controls. We defined PTVs as variants that lead to a premature stop, disrupt canonical splice-sites, or lead to insertions/deletions that shift reading frame. We tested the association of rare <jats:italic>APOB</jats:italic> PTV carrier status with blood lipid levels and CHD. </jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p> Among 29 familial hypobetalipoproteinemia families, 8 families harbored <jats:italic>APOB</jats:italic> PTVs. Carrying 1 <jats:italic>APOB</jats:italic> PTV was associated with 55 mg/dL lower LDL-C ( <jats:italic>P</jats:italic> =3×10 <jats:sup>-5</jats:sup> ) and 53% lower triglyceride level ( <jats:italic>P</jats:italic> =2×10 <jats:sup>-4</jats:sup> ). Among 12 case-control studies, an <jats:italic>APOB</jats:italic> PTV was present in 0.038% of CHD cases as compared to 0.092% of controls. <jats:italic>APOB</jats:italic> PTV carrier status was associated with a 43 mg/dL lower LDL-C ( <jats:italic>P</jats:italic> =2×10 <jats:sup>-7</jats:sup> ), a 30% decrease in triglycerides ( <jats:italic>P</jats:italic> =5×10 <jats:sup>-4</jats:sup> ), and a 72% lower risk for CHD (odds ratio, 0.28; 95% CI, 0.12–0.64; <jats:italic>P</jats:italic> =0.002). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p> Rare PTV mutations in <jats:italic>APOB</jats:italic> which are associated with lower LDL-C and reduced triglycerides also confer protection against CHD. </jats:p> </jats:sec>
収録刊行物
-
- Circulation: Genomic and Precision Medicine
-
Circulation: Genomic and Precision Medicine 12 (5), e002376-, 2019-05
Ovid Technologies (Wolters Kluwer Health)